Validates the use of the RAPID score for predicting mortality in pleural infections, directly informing the management of patients undergoing pleural interventions like chest tubes and medical thoracoscopy.
Abstract
INTRODUCTION: In the updated 9th TNM non-small cell lung cancer (NSCLC) staging edition, pleural and pulmonary metastases remain grouped within the M1a category, inferring similar prognostic implications. The aim was to evaluate the prognostic implication on overall survival (OS) of pleuralcontralateral pulmonary metastases in a stage M1a cohort, when treated with immune checkpoint inhibitors (ICI), chemotherapy, or chemo-ICI. METHODS: Retrospective real-world data from the Netherlands Cancer Registry was used, including patients with M1a NSCLC that received systemic treatment between 2010-2022. The primary outcome was 2-year OS. RESULTS: 5632 patients were included: 2701 with contralateral lung metastases, 2590 with pleural metastases and 341 with both. Pleural metastases were more common in men (p=<0.001), in patients with worse performance score (p=<0.001) and in patients receiving mono-ICI (p=<0.001).Patients with contralateral lung metastases had a better 2-year OS (for chemo, ICI and chemo-ICI, this was 26.9% (95% CI 24.9-28.9), 49.5% (95% CI 43.4-55.2) and 40.4% (95% CI 36.5-44.2), respectively) than patients with pleural metastases (18.5% (95% CI 16.6-20.4), 41.6% (95% CI 36.6-46.5) and 28.6% (95% CI 24.9-32.4), respectively). Patients with both contralateral lung and pleural metastases had the worst OS (12.1% (95% CI 8.2-16.7), 31.1% (95% CI 18.4-44.7) and 25.0% (95% CI 15.7-35.4), respectively). The difference in OS was irrespective of the type of systemic treatment. CONCLUSION: Patients with pleural metastases have inferior OS compared to those with contralateral lung metastases. These findings indicate prognostic heterogeneity between M1a descriptors.
Keep reading
N opens the next oneUltrasound estimation of pleural fluid volume is a core procedural skill for thoracentesis and chest tube placement, making this directly relevant to IP practice.
Directly impacts pleural management and staging by maximizing the diagnostic yield of routine thoracentesis for molecular testing in malignancy.
Pleural fluid obtained during thoracentesis or medical thoracoscopy should be preserved for cfDNA molecular testing when tissue is limited.
Relevant to pleural disease management and post-procedural care of trapped or non-expandable lungs.
Provides useful risk stratification tools for managing secondary spontaneous pneumothorax patients who often require IP intervention.